How to buy Neurobo Pharmaceuticals stock (NRBO)

Neurobo Pharmaceuticals is a biotechnology business based in the US. Neurobo Pharmaceuticals shares (NRBO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.60 – a decrease of 26.94% over the previous week. Neurobo Pharmaceuticals employs 8 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Neurobo Pharmaceuticals stock

Buy Neurobo Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Neurobo Pharmaceuticals stock price (NASDAQ: NRBO)

Use our graph to track the performance of NRBO stocks over time.

Neurobo Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$1.60
52-week range	$1.55 - $6.75
50-day moving average more info button	$2.59
200-day moving average more info button	$3.63
Wall St. target price	$26.67
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-4.29

Is it a good time to buy Neurobo Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Neurobo Pharmaceuticals price performance over time

Historical closes compared with the close of $1.84 from 2024-12-18

1 week (2024-12-13)	-15.98%
1 month (2024-11-21)	-21.70%
3 months (2024-09-20)	-42.32%
6 months (2024-06-21)	-54.68%

1 year (2023-12-21)	-47.35%
2 years (2022-12-21)	-82.17%
3 years (2021-12-21)	372
5 years (2019-12-20)	1800

Neurobo Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-74.35%
Return on equity TTM	-160.76%
Profit margin	0%
Book value	$1.51
Market Capitalization more info button	$20.3 million

TTM: trailing 12 months

Neurobo Pharmaceuticals share dividends

We're not expecting Neurobo Pharmaceuticals to pay a dividend over the next 12 months.

Have Neurobo Pharmaceuticals's shares ever split?

Neurobo Pharmaceuticals's shares were split on a 1:8 basis on 20 December 2023 . So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Neurobo Pharmaceuticals shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Neurobo Pharmaceuticals shares which in turn could have impacted Neurobo Pharmaceuticals's share price.

Neurobo Pharmaceuticals share price volatility

Over the last 12 months, Neurobo Pharmaceuticals's shares have ranged in value from as little as $1.55 up to $6.75. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurobo Pharmaceuticals's is -0.28. This would suggest that Neurobo Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Neurobo Pharmaceuticals has bucked the trend.

Neurobo Pharmaceuticals overview

MetaVia Inc. , a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Neurobo Pharmaceuticals is owned by insiders or institutions?
Currently 65.235% of Neurobo Pharmaceuticals shares are held by insiders and 12.713% by institutions. How many people work for Neurobo Pharmaceuticals?
Latest data suggests 8 work at Neurobo Pharmaceuticals. When does the fiscal year end for Neurobo Pharmaceuticals?
Neurobo Pharmaceuticals's fiscal year ends in December. Where is Neurobo Pharmaceuticals based?
Neurobo Pharmaceuticals's address is: 545 Concord Avenue, Cambridge, MA, United States, 02138 What is Neurobo Pharmaceuticals's ISIN number?
Neurobo Pharmaceuticals's international securities identification number is: US64132R1077 What is Neurobo Pharmaceuticals's CUSIP number?
Neurobo Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 64132R107